SHARE

The average was a result of JAMA Internal Medicine’s study of about 5,900 . Not only did Addyi fail to do what it said it was going to it failed financially. According to David Maris, an analyst at Wells Fargo Securities, sales for Addyi were on pace for $11 million a year. Maris reports Valeant, which owns Addyi, hoped it would make between $100 million and $150 million this year.

 

Today Jezebel reports, citing the New York Times, that taking Addyi results in “half of one satisfying sexual encounter a month” on average. That’s not even enough for the average amount of sex happy couples are having.

 

Addyi (real name flibanserin) became available to the public in October. The pill was supposed to help increase sexual desire targeting the central nervous system. Sprout Pharmaceuticals, who made Addyi, had said clinical trials showed women’s sexual desire increased by 37 percent while taking Addyi. The drug’s actual performance has fallen short of that statistic.

 

People had a lot riding on Addyi, best known as female . Too bad it was a big flop causing what one True Detective character would call “blue balls of the heart.” What’s the point of having access to a Tumblr made to help women have orgasms or this Emma Watson-endorsed site that provides sex advice if some women are struggling just to have the desire to have sex? Addyi was supposed to fix that.